ID1 and neoplasm: Our previous work has revealed that the expression of the dominant negative transcriptional regulator Id1 is a biomarker of poorer prognosis as it is associated with tumor progression, metastasis formation, and tumor-immunosuppression [23,28] in KRAS-driven NSCLC [21].